Veradermics (MANE) VDPHL01 Phase 2/3 Trial Meets Endpoints
Veradermics, Inc. announced positive topline data from its Phase 2/3 clinical trial (Study '302') evaluating VDPHL01 in male patients with mild-to-moderate pattern hair loss (PHL). The trial met all primary and key secondary endpoints with statistical significance, demonstrating rapid onset, consistent response, robust hair count increases, and a favorable tolerability profile. Concurrently, the company is undertaking a public offering of common stock and pre-funded warrants, alongside a private placement (PIPE) to Suvretta Capital affiliates, totaling 3,350,000 securities. As of March 31, 2026, the company reported preliminary unaudited cash, cash equivalents, and marketable securities of approximately $390.8 million.
Key Highlights
- VDPHL01 Phase 2/3 trial (Study '302') in male PHL patients met all primary and key secondary endpoints.
- Patients achieved average non-vellus TAHC increase of 30.3 hairs/cm² (QD) and 33.0 hairs/cm² (BID).
- 79.3% (QD) and 86.0% (BID) of patients reported improved hair coverage on AAIRS vs. 35.6% (placebo).
- Rapid onset of hair growth observed as early as Month 2 with statistically significant separation from placebo.
- Public offering and PIPE to issue aggregate 3,350,000 shares/pre-funded warrants.
- Pre-funded warrants exercise price is public offering price minus $0.00001.
- Cash, cash equivalents, and marketable securities were approximately $390.8M as of March 31, 2026.
- Underwriters have 30-day option to purchase up to 502,500 additional common shares.
Price Impact
More from MANE